Sep 23 2020 de Alencar et al., Clinical Infectious Diseases, doi:10.1093/cid/ciaa1443 Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19) 3% higher mortality (p=0.94) , 16% higher ventilation (p=0.64) , 9% lower ICU admission (p=0.65) , and 10% longer hospitalization (p=0.87)
Plausible hypotheses That is the tension at the heart of the current peptide boom: plausible biology can generate excitement long before it generates reliable clinical evidence
It was originally developed as a medication for type 2 diabetes and also showed effective results in promoting weight loss
While GLP-1 shots are generally well-tolerated, some patients may experience side effects that make it difficult or undesirable to continue treatment
Some phenotypes plausibly need a slower-than-label climb: lighter bodies (higher exposure per milligram), a history of severe GLP-1 gut intolerance, a high baseline heart rate, or a lean, low-reserve build
Does this cover everyone
